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Background: The autonomic nervous system plays a central role in the maintenance
of hemodynamic stability. Cardiac autonomic dysfunction may result in serious
complications, such as sudden cardiac death. Heart rate variability (HRV) is sig-
niﬁcantly reduced in patients undergoing chronic hemodialysis (HD). The aim of
this study was to evaluate the effect of on-line hemodiaﬁltration (OL-HDF) on the
autonomic nervous system in chronic HD patients.
Methods: Forty chronic HD patients were prospectively studied. The participants were
divided into conventional HD and OL-HDF groups. They received regular high-ﬂux HD or
OL-HDF for 4-hour sessions, three times a week. Time-and frequency-domain measures
of the 24-hour HRV were analyzed during the interdialytic period prior to postdilution
OL-HDF and every 6 months for 24 months. The 7-year survival was also evaluated.
Results: Among the 40 participants, 15 patients in the HD group and 11 patients in the
OL-HDF group completed the study. There was no difference in the baseline
characteristics. After 24 months of treatment, β2-microglobulin concentration
decreased (from 33.4715.2 mg/dL to 28.476.2 mg/dL, P ¼0.02) in the OL-HDF group,
while there was no change in the HD group. In the HRV analysis, the frequency-domain
HRV parameters increased signiﬁcantly compared with baseline in the OL-HDF group
[natural logarithmic high frequency (lnHF), 3.1573.36 ms2 vs. 4.4273.81 ms2; ln low
frequency (LF), 3.5673.17 ms2 vs. 4.7873.99 ms2; ln very low frequency (VLF),
4.9074.62 ms2 vs. 6.3875.54 ms2; LF/HF ratio, 1.470.4 vs. 2.570.1]. The survival
rate was similar between the groups.
Conclusion: This study shows that OL-HDF improved autonomic nervous system
dysfunction in chronic HD patients.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Publi
c-nd/4.0/).
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Kidney Res Clin Pract 32 (2013) 127–133128Spectral analysis of heart rate variability (HRV) has emerged
in the past decade as a powerful noninvasive clinical tool for
the assessment of sympathetic and parasympathetic functions
of the autonomic nervous system [1]. Rubinger et al [2]
reported that HRV is signiﬁcantly reduced in patients under-
going chronic hemodialysis (HD), even in the absence of
cardiovascular disease. Decreases in some HRV measures were
suggested to be independent predictors of cardiac death during
long-term follow-up in patients with end-stage renal disease
receiving chronic HD [3].
On-line hemodiaﬁltration (OL-HDF) was introduced as a
model for the effective clearance of middle-to-large molecules
[4]. Compared with standard HD, OL-HDF improves hemody-
namic stability and reduces mortality [5,6].
In a study with 32 dialysis patients, Laaksonen et al [7]
reported that higher Kt/V (41.20) was a predictor of improve-
ment of cardiac autonomic nervous function.
The aim of this study was to evaluate the effect of OL-HDF
on the autonomic nervous system in chronic HD patients. We
hypothesized that OL-HDF improves the autonomic neuropa-
thy in these patients.40 patients
HD
20 patients
Withdrawal
–  2 transfer to other
    hospital
–  1 switch to OL-HDF
–  1 acute coronary
     syndrome
–  1 death
Withdrawal
–  4 transfer to other
    hospital
–  3 switch to HD
–  1 acute coronary
     syndrome
–  1 death
HD
15 patients
OL-HDF
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OL -HDF
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Figure 1. Study population. HD, hemodialysis; OL-HDF, on-line hemo-
diaﬁltration.
Table 1. Baseline characteristics of the study patients
HD (n¼15) OL-HDF (n¼11) P
Age (y) 59.876.5 55.7718.5 0.08
Sex, male 6 (40) 5 (45) 0.57
HD duration (mo) 38.675.8 35.579.1 0.34
Cause of ESRD 0.87
DM 10 (66.7) 7 (63.6)
Hypertension 3 (20.0) 2 (18.2)
Chronic GN 1 (6.7) 2 (18.2)
PCKD 1 (6.7) 0
Comorbidities
DM 10 (66.7) 7 (63.6) 0.56
Hypertension 8 (53.3) 6 (54.5) 0.75
Previous ACS 3 (20.0) 2 (18.2) 0.16
BP medications 8 (53.3) 6 (54.5)
CCB 5 (62.5) 3 (50.0) 0.09
Beta blocker 3 (37.5) 2 (33.3) 0.25
ARB 6 (75.0) 4 (66.7) 0.10
BP, mmHg
Systolic 143.5721.9 146.3719.7 0.12
Diastolic 76.7710.8 79.3713.2 0.10
Data are presented as n (%) or mean7SD.
ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BP,
blood pressure; CCB, calcium channel blocker; DM, diabetes mellitus;
ESRD, end-stage renal disease; GN, glomerulonephritis; HD, hemodia-
lysis; PCKD, polycystic kidney disease.Methods
Patients
Forty outpatients with end-stage renal disease were recruited
who received regular chronic HD therapy for at least 3 months
(4-hour sessions, three times a week, high-ﬂux hemodialysis) at
the hemodialysis room of Kwandong University Myongji Hospital
between 2005 and 2006. The participants were randomized into
conventional HD and OL-HDF groups. Patients with a history of
any of the following medical events were excluded at baseline:
myocardial infarction, stroke, a major surgical procedure within
the previous 2 months, ≥NYHA 3 congestive heart failure,
hemodynamically signiﬁcant valvular or congenital heart disease,
atrial ﬁbrillation or ﬂutter, high grade heart block or a permanent
pacemaker, chronic obstructive lung disease, severe hepatic
disease, malignant neoplasms, or other physical or mental
problems that limit normal daily activities. The study followed
the Helsinki Declaration and Good Clinical Practices.
OL-HDF technique
OL-HDF patients received postdilution OL-HDF for 4 hours,
three times weekly for 24 months with bicarbonate dialysis
ﬂuid and heparin as an anticoagulant. OL-HDF was performed
using the AK200 ULTRA S (Gambro, Lund, Sweden) with
nonreprocessed polyamide dialysis membranes (Polyﬂux 14;
Gambro). Blood ﬂow was maintained at least 250 mL/minute,
the dialysate ﬂow was 600 mL/minute, and the temperature of
the dialysate was approximately 36 1C.
Laboratory methods
Blood samples were drawn every 6 months for routine
laboratory assessments including hemoglobin, blood urea nitro-
gen, creatinine, calcium, phosphorus, albumin, total cholesterol,
triglyceride, uric acid, high sensitivity C-reactive protein, and
β2-microglobulin (β2-MG). The Kt/V was calculated every
6 months for 2 years.HRV analysis
Holter electrocardiogram (ECG) monitoring for 24 hours for
power spectral analysis of the RR intervals was performed in the
inter-dialytic period every 6 months for 24 months. Recorded
Holter ECGs were analyzed using a Holter ECG scanner (Marquette
ECG Analysis Program; GE Medical Systems, Waukesha, WI, USA),
which automatically detected and labeled the QRS complexes. The
results of the automatic analysis were reviewed, and errors in the
R-wave detection and the QRS labeling were edited manually.
For the time-domain HRV measures, the mean normal-to-
normal R-R intervals (NN) and the standard deviation of
the normal-to-normal R-R intervals over the 24 hours (SDNN)
measurements were calculated.
To analyze the frequency-domain HRV measures, the spec-
tral power was quantiﬁed using fast Fourier transformation for
the following frequency bands: 0.15–0.40 Hz (high frequency),
0.04–0.15 Hz (low frequency), 0.003–0.04 Hz (very-low
Table 2. Changes in biochemical parameters
Hemodialysis (n¼15) On-line hemodiaﬁltration (n¼11)
Baseline 6 mo 12 mo 18 mo 24 mo Baseline 6 mo 12 mo 18 mo 24 mo
Hemoglobin (g/dL) 10.071.2 10.071.0 10.171.3 9.471.1 9.870.6 9.171.2 9.671.3 10.371.3 10.470.6* 10.270.9
Calcium (mg/dL) 8.270.6 8.270.8 8.570.9 8.470.6 8.070.7 8.971.4 8.470.7 8.470.6 8.270.9 8.270.8
Phosphorus (mg/dL) 4.971.8 6.071.8 5.171.9 4.371.3 5.272.0 4.571.4 4.771.0* 4.271.4 4.771.2 5.171.7
Glucose (mg/dL) 190.6767.5 180.8765.7 142.9751.7 161.0756.0 159.3774.3 143.0783.0 156.8765.3 139.1739.1 131.3739.3 120.3738.2
BUN (mg/dL) 50.5717.0 60.1717.8 66.5719.1 61.2723.5 69.9718.6 58.6718.1 48.4714.4 56.0711.5 68.3723.8 56.9717.9
Creatinine (mg/dL) 8.472.1 9.172.6 9.673.3 9.772.0 10.171.9 9.272.5 8.573.0 8.872.5 9.973.0 9.972.9
Uric acid (mg/dL) 6.571.0 6.671.3 7.271.4 7.271.6 7.871.5 6.971.5 6.670.8 7.070.8 7.971.7 7.671.5
Total cholesterol (mg/dL) 154.4734.7 149.5724.3 155.0758.9 143.6738.1 147.6738.9 137.0726.9 126.1723.0 125.9733.0 130.3721.3 121.2724.3
Albumin (g/dL) 3.570.4 3.770.4 3.770.2 3.570.5 3.670.4 3.370.5 3.370.5* 3.670.4 3.570.3 3.570.5
Triglyceride (mg/dL) 120.5750.4 147.3789.4 103.6757.9 72.7727.4 91.474v3.4 136.8792.4 114.1734.3 94.4732.4 114.3732.2* 86.3722.5
HDL-cholesterol (mg/dL) 40.4712.5 37.3712.0 37.8714.6 37.8713.8 38.477.9 32.976.5 29.674.1 32.777.6 30.774.3 30.274.6
Na (mEq/L) 139.372.9 139.373.2 140.373.3 140.873.9 138.572.7 141.274.1 140.172.0 141.372.4 139.272.6 141.372.3
K (mEq/L) 4.771.0 4.970.7 5.071.7 5.370.8 5.470.7 4.771.3 4.971.1 5.170.9 5.270.9 5.070.8
Cl (mEq/L) 97.573.4 88.3730.5 101.774.1 99.372.6 101.471.7 99.074.8 100.3713.9 100.072.5 101.374.3 99.272.0
Total CO2 (mEq/L) 22.972.2 22.673.6 21.273.8 20.673.1 21.872.6 23.972.9 23.071.3 23.471.7 22.373.3 23.573.4
β2-MG (mg/dL) 34.6716.3 32.378.6 31.775.9 33.4713.4 37.379.1 33.4715.2 25.978.5*,
†
26.376.0*,
†
26.979.2*,
†
28.476.2*,
†
PTH (pg/mL) 176.3797.3 193.8739.1 188.07148.1 151.47134.9 198.47114.6 190.8787.6 141.5753.6 265.07219.1 224.97182.1 220.27278.8
CRP (mg/dL) 0.670.9 0.670.8 0.570.7 0.871.6 0.671.1 1.171.6 1.770.9 0.470.4 0.570.6 0.570.8
Kt/V 1.270.4 1.370.9 1.370.8 1.371.4 1.371.2 1.270.5 1.370.8 1.470.9 1.370.9 1.371.3
n Po0.05 vs. HD.
† Po0.05 vs. baseline.
Data are presented as mean7SD.
β2-MG, β2-microglobulin; BUN, blood urea nitrogen; CRP, C-reactive protein; HDL, high-density lipoprotein; PTH, parathyroid hormone.
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Kidney Res Clin Pract 32 (2013) 127–133130frequency), and ≤0.003 Hz (ultra-low frequency). The var-
iances were transformed to natural logarithmic (ln) values.
Outcome measures
The primary outcome was improvement of autonomic neuro-
pathy assessed with HRV, and the secondary outcomewas 7-year
mortality. The patients were followed for mortality analysis until
December 2012 or until they received a kidney transplant. We
regarded transplants as censored cases. For patients who moved
to other facilities, we recruited the mortality data by telephone.
Statistical analysis
Continuous data are reported as the mean7standard
deviation. Categorical data are presented as absolute values
and percentages. The differences between the two groups
were tested using the Fisher exact or the Chi-square test for
categorical variables and the Student t test or Mann–Whitney
test for continuous data. The serial HRV measures were
compared within and between the groups using repeated-
measures analysis of variance. We performed a survival
analysis using the Kaplan–Meier survival curve. All the statis-
tical analyses were performed using SPSS software version
19.0 (IBM, Chicago, IL, USA). A 2-tailed Po0.05 was considered
to be statistically signiﬁcant.Ta
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Among the 40 patients, 15 patients in the HD group and 11
patients in the OL-HDF group completed the entire study
(Fig. 1). Two patients died during the study period: one in
the HD group from sepsis, and one in the OL-HDF group from
gastric ulcer bleeding. In total, 26 patients were included in
the study. The baseline characteristics are compared in Table 1.
The HD and OL-HDF groups showed similar characteristics.
The median age of the patients was 61 years in both groups
(ranges, 49–70 years in HD group and 36–80 years in OL-HDF
group). The mean dialysis vintages were 38.6 months (range,
3–125 months) and 35.3 months (range, 3–160 months) in the
HD and OL-HDF groups, respectively.
The baseline laboratory ﬁndings including hemoglobin,
calcium, phosphorus, blood urea nitrogen, creatinine, albumin,
electrolytes, parathyroid hormone, C-reactive protein, β2-MG,
and Kt/V were not different between the HD and OL-HDF
groups (Table 2).
During the 24-month follow up, β2-MG concentration
exhibited a nonsigniﬁcant increase in the HD group (34.67
16.3 mg/dL to 37.379.1 mg/dL, P¼0.060) and a signiﬁcant
decrease in the OL-HDF group (33.4715.2 mg/dL to 28.47
6.2 mg/dL, P¼0.013).
Changes of HRV parameters
Table 3 shows the HRV parameters. The baseline HRV
measures were not different between the HD and OL-HDF
groups. There was no difference in the time-domain measures
during the follow-up period between the HD and OL-HDF
groups except for low SDNN in the HD group and high mean
NN in the OL-HDF group at 24 months. The frequency-domain
measures were obviously different between the two groups.
The frequency-domain measures did not differ between the
Figure 2. Changes of the heart rate variability measurement. The frequency domain parameters [(A) very low frequency, VLF; (B) high frequency,
HF; (C) low frequency, LF] increased during on-line hemodiaﬁltration (OL-HDF) treatment. n Po0.05 vs. hemodialysis, † Po0.05 vs. baseline. NN,
normal-to-normal R-R intervals; SDNN, standard deviation of normal-to-normal R-R intervals during 24 h.
Figure 3. Kaplan–Meier curves comparing survival in the hemodia-
lysis (HD) and on-line hemodiaﬁltration (OL-HDF) patients. There is
no statistically signiﬁcant difference in survival (P40.05).
Park et al / The effect of on-line HDF on HR variability 131two groups at baseline but increased continuously over time in
the OL-HDF group (Fig. 2).
Survival analysis
Five patients in the HD group and four patients in the
OL-HDF group transferred to other facilities after the study
completion. Among patients who stayed at our hospital, seven
in the HD group and four in the OL-HDF group maintained
their HD modality without change.
Five patients in the HD group (45.5%) and seven patients in
the OL-HDF group (46.7%) died during the follow-up period.
The Kaplan–Meier survival curve showed that the cumulative
survival was not different between the groups (Fig. 3).Discussion
The major ﬁnding of our study was that OL-HDF improved
autonomic nervous system dysfunction measured by HRV in
chronic HD patients.
Many HD patients have autonomic neuropathy. Ewing DJ
and Winney R [8] found that half of the HD patients exhibited
autonomic neuropathy using three simple methods includingresponses to the Valsalva maneuver, handgrip response, and
beat-to-beat variation of the heart beat at rest. Several studies
have reported that hypotension during HD may be caused by
autonomic neuropathy [9–11]. Many of HD patients without
intradialytic hypotension also experience autonomic neuropa-
thy symptoms including impotence, postural dizziness, and
uremic pruritus [12–14].
Analysis of HRV has been used as a noninvasive tool to assess
the autonomic nervous system. Although there are various ways
of quantifying HRV, including time domain, frequency domain,
and nonlinear analysis, one method has not been established as
superior to another [15–17]. Recently, Suzuki et al [18] reported
that nonlinear measures of HRV had predictive value for
mortality in HD patients. We analyzed HRV conventionally
using 24-hour Holter ECGs for time and frequency domain
analyses according to the guidelines [19].
Uremic cardiac autonomic neuropathy may be characterized
by reduced HRV indicating cardiac sympathetic overactivity and
parasympathetic deterioration [20]. Several studies have
reported reduced HRV [21] and its association with left ven-
tricular hypertrophy [22] and increased CKD-related hospitali-
zation [23].
The role of dialysis in autonomic neuropathy has been
reported by several investigators. Leem et al [24] reported
that dialysis did not alter autonomic nerve function during the
ﬁrst 12 months of HD. However, Laaksonen et al [7] found that
the improvement in HRV occurred only in patients who had a
Kt/V41.2. Progressive deterioration of autonomic neuropathy
was associated with a Kt/Vo0.87. In addition, Dursun et al [25]
suggested that dialysis for 12 months improved autonomic
dysfunction, especially in continuous ambulatory peritoneal
dialysis (CAPD).
Genovesi et al [26] suggested a potential autonomic advan-
tage with convective treatment (hemoﬁltration) compared
with diffusive treatment (hemodialysis) during both interdia-
lytic and intradialytic periods using spectral analysis of HRV.
The role of convection in treatment of autonomic neuropathy
is not fully understood. Santoro et al [27] suggested that
hemoﬁltration acts through less negative sodium balance
and effective removal of vasodilating or autonomic nervous
inhibitory substances. In the present study, OL-HDF for 24
months improved autonomic neuropathy measured by HRV
analysis. It is well known that many patients with systemic
amyloidosis have autonomic neuropathy and they show abnor-
mal HRV [28,29]. Most uremic patients have high β2-MG
concentration and this causes uremic amyloidosis. In our study,
Kidney Res Clin Pract 32 (2013) 127–133132OL-HDF effectively removed β2-MG with the convective
method; however, we cannot ﬁnd any causal relationship
between β2-MG and autonomic neuropathy. Rubinger et al [2]
reported that renal transplantation normalized HRV in most
uremic patients except the amyloidosis patients with cardiac or
adrenal involvement. However, they did not reveal the relation-
ship between β2-MG and HRV.
In contrast to previous studies, we failed to show improved
survival in the patients treated with OL-HDF [6,30]. The small
study population and the inability of some patients to main-
tain their HD modality after moving to other hospitals might
be barriers to conﬁrming improved survival.
Our study has several limitations. First, the sample size was
small and the study was performed at a single center. It is
well known that the majority of HD patients are diabetics and
abnormal HRV is very common in patients with diabetes regard-
less of renal function [31,32]. Unfortunately, because of the small
sample size, we could not compare the effect of OL-HDF on HRV in
diabetics with nondiabetics. Second, we recorded Holter electro-
cardiography during the interdialytic period, which may not incor-
porate intradialytic arrhythmia. Third, we were unable to obtain
information concerning the HD modality, (i.e., HD vs. OL-HDF) in
the patients who were transferred to other facilities.
To our knowledge, this is the ﬁrst prospective study to
examine the effect of OL-HDF on autonomic neuropathy in
chronic HD patients. Large-scale studies are required to con-
ﬁrm the role of OL-HDF in the improvement of autonomic
neuropathy in HD patients.Conﬂicts of interest
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